IL6 and Sepsis: Depending on this view, exogenous administration of rmMFG-E8 attenuated inflammation by reducing pro-inflammatory cytokines, TNF-α, IL-6 and IL-1β in sepsis as well as other diseases where LPS-TLR4 signaling is predominant [4], [5].